30.1 C
New York
Sunday, June 7, 2026

Tag: healthcare products

J-Star Holding Announces Pricing of $5.0 Million Initial Public Offering

TAICHUNG CITY, Taiwan, July 29, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications including personal sports equipment, healthcare products, automobile parts, resin systems, and research and development services, today announced the pricing of its public offering of an aggregate 1,250,000 ordinary shares of the Company (the “Offering”). The offering is priced at $4.00 per share (the “Offering Price”).

Knee Replacement Surgery Market worth $16.17 billion in 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025...

Johnson & Johnson showcases latest advancements in Alzheimer’s research at AAIC 2025

Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection New findings highlight the central role of...

TraceLink Updates ISO 9001 Certification to Support Scalable, Compliant Supply Chain Innovation

Independent audit confirms TraceLink's operational rigor and readiness to meet evolving customer and regulatory demands BOSTON, July 23, 2025 /CNW/ -- TraceLink, the largest end-to-end digital network...

TraceLink Updates ISO 9001 Certification to Support Scalable, Compliant Supply Chain Innovation

Independent audit confirms TraceLink's operational rigor and readiness to meet evolving customer and regulatory demands BOSTON, July 23, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network...

TraceLink Updates ISO 9001 Certification to Support Scalable, Compliant Supply Chain Innovation

Independent audit confirms TraceLink's operational rigor and readiness to meet evolving customer and regulatory demands BOSTON, July 23, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network...

TraceLink Updates ISO 9001 Certification to Support Scalable, Compliant Supply Chain Innovation

Independent audit confirms TraceLink's operational rigor and readiness to meet evolving customer and regulatory demands BOSTON, July 23, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network...

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 5, 2025 to report its second quarter 2025 financial results and provide a corporate update.

Healthcare Consulting Services Market Worth $51.95 Billion by 2030 with 10.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 21, 2025 /PRNewswire/ -- The global Healthcare Consulting Services Market, valued at US$29.11 billion in 2024, stood at US$32.17  billion in...

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies

AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

AscellaHealth Launches Q2 2025 Specialty & Rare Pipeline Digest™ to Support Stakeholders Navigating Specialty Drug Growth

AscellaHealth Launches Q2 2025 Specialty & Rare Pipeline Digest™ to Support Stakeholders Navigating Specialty Drug Growth

Genfit : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 8 juillet 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui le bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHealthcare products